Vittorio Luigi Garosi

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Jean‐Luc Van Laethem, Hanno Riess, Jacek Jassem et al. · Targeted Oncology · 2016 · 60 citations

Pancreatic Cancer, Gastrointestinal Oncology, Phase I/ii Study +10

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial

Guillem Argilés, Mark Saunders, Fernando Rivera et al. · European Journal of Cancer · 2015 · 53 citations · Full text

Modified Folfox6, Gastrointestinal Oncology, Medicine +9

Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial

Michele O. Carruba, Massimo Cuzzolaro, Laura Riva et al. · International Clinical Psychopharmacology · 2001 · 52 citations

Obesity, Nutrition, Hypertension +14

Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient

B Neri, Vittorio Luigi Garosi, Claudio Intini · Anti-Cancer Drugs · 1997 · 31 citations

Medroxyprogesterone Acetate, Megestrol Acetate, Oncology +13

Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Anthony B. El-Khoueiry, Richard D. Kim, William Proctor Harris et al. · Journal of Clinical Oncology · 2021 · 18 citations

First-line Treatment, Pharmacotherapy, Immunotherapy +20